{"id":"NCT01722604","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2012-11-07","resultsPosted":"2021-06-09","lastUpdate":"2023-05-09"},"enrollment":258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},"conditions":["Glaucoma","Open Angle or Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"brinzolamide 1% ophthalmic suspension","otherNames":[]},{"type":"DRUG","name":"Azopt 1%","otherNames":[]}],"arms":[{"label":"Azopt 1% ophthalmic suspension","type":"ACTIVE_COMPARATOR"},{"label":"Brinzolamide 1% ophthalmic suspension","type":"EXPERIMENTAL"}],"summary":"The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.","primaryOutcome":{"measure":"Intraocular Pressure (IOP) at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Brinzolamide 1% Ophthalmic Suspension","deltaMin":20.6,"sd":3.21},{"arm":"Azopt 1% Ophthalmic Suspension","deltaMin":20.8,"sd":3.37}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":["Instillation site complication"]}}